Deal of the Day — limited-time pharmacy picks!
Xovoltib 40mg tablet

Xovoltib 40mg tablet

Prescription requiredRx Required

Salt Composition: Afatinib

Expiry Date: 01/2028

Special offer

Price on Request

Price on Request

Inclusive of all taxes

▼

28 tablet

About The Product

Non-small cell lung cancer (NSCLC)

  • Xovoltib 40 mg (afatinib) is a prescription medication meant for the management of lung cancer, particularly non-small cell lung cancers characterized by EGFR mutations.
  • The mechanism of action entails inhibition of signals that promote proliferation and spreading of the cancer cells, and it is prescribed to individuals who are resistant to platinum-based chemotherapy drugs.
  • Xovoltib is taken once daily in its entirety and swallowed with plain water without eating prior to intake.
  • Side effects of Afatinib 40mg include diarrhea, skin rash, dry skin, skin irritation, mouth sores, and nausea.
  • Medical observation is important, especially among individuals with liver diseases, kidney disorders, and lung conditions.
  • This drug should not be prescribed to pregnant or lactating women.

Side Effects

Xovoltib 40mg tablet may cause some side effects that vary from one patient to another. Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Contact the doctor immediately in case of any severe or unusual side effects. Side effects include:

​Common Side Effects:

  • Diarrhea (sometimes severe, leading to dehydration)
  • Nausea, vomiting, or loss of appetite
  • Fatigue and weakness
  • Headache and dizziness (including vertigo or fainting)
  • Abdominal pain or discomfort
  • Rash, acne‑like eruptions, dry skin, or itching
  • Mouth sores (stomatitis)
  • Nail changes or infections
  • Hair thinning or loss
  • Eye irritation, dryness, or other vision problems
  • Respiratory infections, cough, or breathlessness

Serious Side Effects

  • Liver problems (including elevated enzymes or liver toxicity)
  • Kidney issues
  • Heart complications (such as QT interval prolongation or heart failure)
  • Bleeding disorders or hemorrhage
  • Low blood counts (anemia, neutropenia, or reduced platelets)
  • Interstitial lung disease or pneumonitis

How To Use

  • ​It is prescribed by the doctor; hence, it is advisable to follow the prescription given.
  • Xovoltib 40mg tablets are taken orally once every day on an empty stomach.
  • Swallow the whole Afatinib tablet with water. Avoid breaking, crushing, or chewing it.


Safety Advice

Alcohol
Consult your doctor as the interaction of alcohol with this drug is still unknown, but you should avoid the consumption of alcohol while taking Xovoltib 40mg tablet.
Pregnancy
Do not take Xovoltib 40mg tablet during pregnancy, as it is a highly unsafe medicine for the fetus.
Breast Feeding
Xovoltib 40mg tablet is unsafe to use during breastfeeding as it may cause toxicity to the baby.
Driving
Xovoltib 40mg tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving or operating heavy machinery.
Kidney
Consumption of Xovoltib 40mg tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
Consumption of Xovoltib 40mg tablet should be avoided without informing the doctor if you have any liver-related issues.

Missed Doses

  • ​It is advisable to avoid missing any doses.
  • In case you miss a dose of Xovoltib, consult your doctor immediately.
  • Take your Xovoltib 40mg tablet as soon as you can if you miss a dose.
  • On the other hand, if your next dose is almost due, skip the missed one and resume your usual routine. Don't take it twice.

FAQs

​Xovoltib is an anticancer tablet that is primarily used in the treatment of non-small cell lung cancer.


References

  • Wecker, H., & Waller, C. F. (2018). Afatinib. Small Molecules in Oncology, 199-215.
  • Keating, G. M. (2016). Afatinib: a review in advanced non-small cell lung cancer. Targeted oncology, 11(6), 825-835 - https://pubmed.ncbi.nlm.nih.gov/27873136/
  • Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020). Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings. Journal of Oncology Pharmacy Practice, 26(6), 1461-1474 - https://pubmed.ncbi.nlm.nih.gov/32567494/
  • Keating, G. M. (2014). Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs, 74(2), 207-221 - https://pubmed.ncbi.nlm.nih.gov/24435321/
  • Nelson, V., Ziehr, J., Agulnik, M., & Johnson, M. (2013). Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. OncoTargets and therapy, 135-143 - https://pubmed.ncbi.nlm.nih.gov/23493883/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026